| Name | Title | Contact Details |
|---|
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.
GeneSage is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stem Centrx is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.